Published in Oncotarget on December 01, 2012
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res (2014) 1.75
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res (2014) 1.29
Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med (2014) 1.19
Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep (2014) 1.19
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget (2015) 1.12
Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One (2014) 1.10
BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U S A (2014) 1.05
Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget (2014) 1.02
Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem (2014) 1.01
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. Oncotarget (2015) 1.01
BRD4: a BET(ter) target for the treatment of AML? Cell Cycle (2014) 0.99
BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther (2014) 0.98
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget (2016) 0.87
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells (2014) 0.85
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells. Blood Cancer J (2015) 0.83
LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. Elife (2014) 0.83
Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol (2014) 0.83
Targeted drug discovery for pediatric leukemia. Front Oncol (2013) 0.82
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget (2013) 0.82
Identification of small molecule modulators of gene transcription with anticancer activity. ACS Chem Biol (2014) 0.82
Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells. Semin Hematol (2015) 0.80
H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription. Oncotarget (2015) 0.80
BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Stem Cell Res Ther (2016) 0.79
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia (2015) 0.78
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Leukemia (2016) 0.78
Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol (2015) 0.78
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia. Ther Adv Hematol (2015) 0.78
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms. Proc Natl Acad Sci U S A (2016) 0.78
The molecular mechanics of mixed lineage leukemia. Oncogene (2016) 0.76
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget (2016) 0.76
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects. Onco Targets Ther (2016) 0.76
Future prospects of therapeutic clinical trials in acute myeloid leukemia. Future Oncol (2016) 0.75
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget (2016) 0.75
Targeting leukemia stem cells: in vitro veritas? Oncotarget (2014) 0.75
Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling. Cell Commun Signal (2017) 0.75
Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics (2016) 0.75
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 13.98
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 6.82
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol (2004) 5.10
The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem (2007) 5.06
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol (2011) 3.34
The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia (2000) 3.32
Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell (2009) 3.29
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Targeting epigenetic readers in cancer. N Engl J Med (2012) 2.86
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood (2005) 2.28
Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. Br J Haematol (2007) 2.08
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 1.99
BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A (2012) 1.93
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol (2008) 1.57
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol Cell Biol (2004) 1.47
Targeting leukemic stem cells by breaking their dormancy. Mol Oncol (2010) 1.36
Punish the parent not the progeny. Blood (2004) 1.32
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2008) 1.32
Independent prognostic variables in acute myeloid leukaemia. Blood Rev (2010) 1.29
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget (2011) 1.27
Considerations for targeting malignant stem cells in leukemia. Cancer Control (2004) 1.20
Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. Leuk Lymphoma (2006) 1.16
Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol (2009) 1.11
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest (2007) 1.11
Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice. Oncotarget (2012) 1.07
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol (2009) 1.06
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets (2011) 0.98
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood (2011) 0.94
Molecular targeted therapy in acute myeloid leukemia. Hematology (2012) 0.91
Targeting the acute myeloid leukemia stem cells. Anticancer Agents Med Chem (2010) 0.88
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. Curr Cancer Drug Targets (2012) 0.86
Novel therapeutic agents in acute myeloid leukemia. Exp Hematol (2007) 0.86
Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. Semin Oncol (2008) 0.86
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica (2011) 0.83
Human leukaemic stem cells: a novel target of therapy. Eur J Clin Invest (2004) 0.82
Novel therapeutic strategies for AML in 2012. Hematology (2012) 0.81
Cellular signalling pathways: new targets in leukaemia therapy. Br J Haematol (2002) 0.81
[Allogeneic stem cell transplantation in the management of acute myeloid leukemia]. Med Klin (Munich) (2007) 0.78
Molecular targets in acute myelogenous leukemia. Blood Rev (2003) 0.78
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Transcriptional amplification in tumor cells with elevated c-Myc. Cell (2012) 8.24
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Direct inhibition of the NOTCH transcription factor complex. Nature (2009) 4.82
DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol (2008) 4.56
Global regulation of erythroid gene expression by transcription factor GATA-1. Blood (2004) 4.22
The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science (2013) 4.20
Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Small-molecule inhibition of BRDT for male contraception. Cell (2012) 3.50
Exchange of GATA factors mediates transitions in looped chromatin organization at a developmentally regulated gene locus. Mol Cell (2008) 3.24
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res (2007) 2.97
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell (2011) 2.69
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J (2005) 2.53
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immunoprecipitation. Biotechniques (2006) 2.46
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev (2012) 2.44
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol (2010) 2.40
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood (2008) 2.19
BET bromodomains mediate transcriptional pause release in heart failure. Cell (2013) 2.17
TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol (2009) 2.15
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev (2013) 2.12
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell (2011) 2.11
Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. Angew Chem Int Ed Engl (2007) 2.11
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev (2013) 2.07
Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res (2012) 2.06
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood (2008) 2.04
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol (2011) 2.02
Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol (2010) 1.98
A reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Mol Cell (2009) 1.94
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle (2012) 1.88
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Mol Cell Biol (2007) 1.84
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood (2009) 1.84
Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol (2011) 1.82
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res (2011) 1.82
A pipeline for the generation of shRNA transgenic mice. Nat Protoc (2012) 1.76
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol (2003) 1.72
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res (2004) 1.71
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood (2014) 1.68
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun (2012) 1.67
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med (2012) 1.67
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res (2011) 1.65
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res (2013) 1.64
Mastocytosis: state of the art. Pathobiology (2007) 1.64
Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. J Am Chem Soc (2008) 1.64
Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol (2011) 1.63
The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol (2004) 1.63